相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
A. Nakao et al.
CANCER GENE THERAPY (2011)
A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
Martijn P. Lolkema et al.
CLINICAL CANCER RESEARCH (2011)
GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy
Guru Sonpavde et al.
CLINICAL CANCER RESEARCH (2011)
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Tae-Ho Hwang et al.
MOLECULAR THERAPY (2011)
Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
Kevin J. Harrington et al.
CLINICAL CANCER RESEARCH (2010)
REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
Charles Comins et al.
CLINICAL CANCER RESEARCH (2010)
Intravenous administration of ReolysinA®, a live replication competent RNA virus is safe in patients with advanced solid tumors
Radharani Gollamudi et al.
INVESTIGATIONAL NEW DRUGS (2010)
Reovirus-based therapy for cancer
Kevin Kelly et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Laura Vidal et al.
CLINICAL CANCER RESEARCH (2008)
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
Jian Qiao et al.
CLINICAL CANCER RESEARCH (2008)
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial
C. L. White et al.
GENE THERAPY (2008)
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
Peter Forsyth et al.
MOLECULAR THERAPY (2008)
Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release
Paola Marcato et al.
MOLECULAR THERAPY (2007)
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
SA Laurie et al.
CLINICAL CANCER RESEARCH (2006)
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
AI Freeman et al.
MOLECULAR THERAPY (2006)
Recent progress in the battle between oncolytic viruses and tumours
KA Parato et al.
NATURE REVIEWS CANCER (2005)
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin
TR Reid et al.
CANCER GENE THERAPY (2005)
JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells
P Clarke et al.
JOURNAL OF VIROLOGY (2004)
A novel intravesical therapy for superficial bladder cancer in an orthotopic model: Oncolytic reovirus therapy
EG Hanel et al.
JOURNAL OF UROLOGY (2004)
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
EA Chiocca et al.
MOLECULAR THERAPY (2004)
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
AL Pecora et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene -: Deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer
PA Vasey et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Reovirus oncolysis of human breast cancer
KL Norman et al.
HUMAN GENE THERAPY (2002)
Reovirus as an oncolytic agent against experimental human malignant gliomas
ME Wilcox et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Reovirus-induced apoptosis requires activation of transcription factor NF-κB
JL Connolly et al.
JOURNAL OF VIROLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
